In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Genetic spectrum of hypertrophic cardiomyopathy revisited. Whole Exome Sequencing reveals extreme genetic heterogeneity and new gene mutations in a multicenter series of 200 patients

Session Poster Session 7

Speaker Karine Nguyen

Congress : ESC Congress 2018

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Poster Session
  • FP Number : P6324

Authors : KN Nguyen (Marseille,FR), SR Roche (Marseille,FR), CL Lavoute (Marseille,FR), PR Reant (Bordeaux,FR), ED Donal (Rennes,FR), JH Haentjens (Marseille,FR), EC Consolino (Marseille,FR), SO Odent (Rennes,FR), JCE Eicher (Dijon,FR), LF Faivre (Dijon,FR), CRT Rooryck- Thambo (Bordeaux,FR), PC Charron (Paris,FR), ACC Casalta (Marseille,FR), NM Michel (Marseille,FR), G Habib (Marseille,FR)

Authors:
K.N. Nguyen1 , S.R. Roche1 , C.L. Lavoute1 , P.R. Reant2 , E.D. Donal3 , J.H. Haentjens1 , E.C. Consolino1 , S.O. Odent3 , J.C.E. Eicher4 , L.F. Faivre4 , C.R.T. Rooryck-Thambo2 , P.C. Charron5 , A.C.C. Casalta1 , N.M. Michel1 , G. Habib1 , 1la Timone Hospital - Marseille - France , 2University Hospital of Bordeaux - Bordeaux - France , 3University of Rennes - Rennes - France , 4University Hospital of Dijon - Dijon - France , 5Centre de référence des maladies cardiaques héréditaires - Paris - France ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 1323

Background and objectives: Hypertrophic cardiomyopathy (HCM) is expected to be caused by a heterozygous mutation in one of the 5 main sarcomere genes (MYBPC3, MYH7, TNNT2, MYL2, TNNI3). However, the routine diagnostic strategy consisting of the sequencing of these 5 genes allows identification of a mutation in only 50% of familial or sporadic cases, limiting accurate genetic counseling in families and predictive diagnosis in at-risk subjects.

Purpose: We aimed at evaluating the value of Whole Exome Sequencing (WES), comparing its diagnostic yield with the routine diagnostic strategy, and clarifying the genetic spectrum of HCM.

Methods: We performed WES in a large series of 200 new unrelated patients with primary HCM using the Agilent SureSelect V6 technology on Illumina Hiseq 2500. Patients were recruited between June 2015 and October 2016 in 5 French centers. In a first step of analysis, a panel of 145 genes involved in various hereditary cardiac diseases was searched for mutations. Bioinformatics analyses were performed in our lab. Only “certainly” (class 5) or “probably” pathogenic (class 4) mutations were considered, according to current guidelines

Results: A total of 565 filtered variants predicted as pathogenic in 111 genes were retained after bioinformatics analysis, literature and databases review. The main results are the following:

– A mutation in 1 of the 5 main sarcomere genes was observed in only 72 (36%) patients, with no mutation on the TNNI3 gene.

– Conversely, 495 other pathogenic mutations were identified in 185 patients, giving a total 92.5% detection rate of at least one pathogenic gene mutation. Among them, the most prevalent mutated genes were FLNC, LDB3, MYPN, ANK2, RYR2 and NEBL. In addition, unexpected diagnosis of treatable affections such as Fabry disease (n=1) and TTR amyloidosis (n=1) were identified by WES analysis

– A single mutation was identified in only 27 patients (13.5% of cases). In 158 patients (79%), multiple variants were identified with 2 to 8 mutations per patient.

– Finally, in only 15 patients (7.5%), no mutation was identified in this panel of 145 genes.

Conclusions: 1. Exome sequencing improves the diagnostic output in HCM with 92.5% of patients carrying at least one pathogenic mutation in a panel of 145 genes involved in various hereditary cardiac diseases

2. Genetic heterogeneity is much larger than expected with multiple variants in sarcomere genes, but also non-sarcomere, and ion channel genes unexpected in HCM.

3. Early unexpected diagnosis of Fabry disease or TTR amyloidosis can be obtained by our strategy of one-step large genetic analysis.

4. Our results suggest that the commonly accepted monogenic model of HCM involving one mutation in one gene is not the major mechanism in HCM. Rather, oligogenism with 1 major and several minor variants is our proposed new pathogenic mechanism in HCM.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are